Please assess the completion status of the following clinical trial:

Trial Title: Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Laboratory-confirmed SARS-CoV-2 infection as determined by an approved polymerase chain reaction (PCR) or an approved antigen test of any specimen~* Hospitalized with COVID-19-induced ARD or ARDS (any severity) with a PaO2/FiO2 (PF ratio) ≤ 300~* Requires oxygen supplementation at Screening~* Willing to follow contraception guidelines~Exclusion Criteria:~* Current standard of care treatments for COVID-19 appear to be working and the subject is clinically improving~* A previous stem cell infusion unrelated to this trial~* Certain medical conditions that pose a safety risk to the subject~* Pregnant or breast feeding or planning to during the study~* Suspected uncontrolled active bacterial, fungal, viral, or other infection~* History of splenectomy, lung transplant, or lung lobectomy~* Concurrent participation in another clinical trial involving therapeutic interventions~* Expected survival or time to withdrawal of life-sustaining treatments expected to be \<7 days~* Has an existing Do Not Intubate order~* Has undergone home mechanical ventilation (noninvasive ventilation or via tracheotomy) expect for continuous positive airway pressure or bi-level positive airway pressure (CPAP/BIPAP) used solely for sleep-disordered breathing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- COVI-MSC (Type: EXPERIMENTAL): Subjects will receive intravenous infusions of COVI-MSC (two vials or a total of ≈ 30 million cells) on Day 0, Day 2, and Day 4
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will receive intravenous infusions of placebo (two vials) on Day 0, Day 2, and Day 4

Based on this trial design, predict the completion outcome and termination type (if applicable).